Table 1.
Baseline characteristics of patients
| Characteristics, n (%) | Selumetinib + docetaxel (N = 35) | Selumetinib + dacarbazine (N = 25) |
|---|---|---|
| Age, years; mean (SD) | 58.9 (9.5) | 57.1 (11.5) |
| Male | 21 (60.0) | 15 (60.0) |
| Female | 14 (40.0) | 10 (40.0) |
| Race | ||
| White | 33 (94.3) | 25 (100.0) |
| Black/African American | 2 (5.7) | 0 |
| WHO performance status | ||
| 0 | 14 (40.0) | 12 (48.0) |
| 1 | 21 (60.0) | 13 (52.0) |
| Primary tumor site | ||
| Skin/soft tissue | 11 (31.4) | 17 (68.0) |
| Lung | 8 (22.9) | 3 (12.0) |
| Breast | 3 (8.6) | 0 |
| Colorectal | 2 (5.7) | 0 |
| Esophagus | 2 (5.7) | 0 |
| Ovary | 2 (5.7) | 0 |
| Head and neck | 1 (2.9) | 1 (4.0) |
| Uveal | 1 (2.9) | 1 (4.0) |
| Othera | 5 (14.3) | 3 (12.0) |
| Mean prior systemic treatments | 3.1 | 2.0 |
| Prior therapy, n (%) | ||
| Chemotherapy | 30 (85.7) | 18 (72.0) |
| Platinum compounds | 24 (68.6) | 9 (36.0) |
| Taxanes | 18 (51.4) | 8 (32.0) |
| Pyrimidine analogues | 6 (17.1) | 1 (4.0) |
| Anthracyclines | 5 (14.3) | 3 (12.0) |
| Radiotherapy | 18 (51.4) | 13 (52.0) |
| Other systemic anticancer therapyb | 8 (22.9) | 8 (32.0) |
| Immuno/hormonal therapy | 6 (17.1) | 0 |
| Hormonal therapy | 3 (8.6) | 0 |
| Immunotherapy | 2 (5.7) | 10 (40.0) |
| Prior lines of chemotherapy, n (%) | ||
| 0 or 1 | 17 (48.6) | 21 (84.0) |
| 2 or 3 | 10 (28.6) | 2 (8.0) |
| 4+ | 8 (22.9) | 2 (8.0) |
aIncludes bladder, lymph nodes, melanoma, muscle, prostate, pancreas, stomach, unknown primary, and uterus
bIncludes monoclonal antibodies, vaccines, small molecule targeted agents, and investigational drugs
SD, standard deviation; WHO, World Health Organization